Hanmi

Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Hanmi Pharmaceutical, Medication, Partnership, U.S. Securities and Exchange Commission, FDA, SPPI, Quality control, Board, Board of directors, Spectrum Pharmaceuticals, Patient, Nasdaq, Security (finance), SVP, Hanmi, Forward-looking statement, Growth, Pharmaceutical industry, Management, Spectrum

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.

Key Points: 
  • Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.
  • We are delighted to have Ms. Lim join Spectrums Board of Directors, said William Ashton, Chairman of the Board, Spectrum Pharmaceuticals.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical

Retrieved on: 
Tuesday, January 4, 2022
Medical Devices, FDA, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Safety, Growth, Spectrum Pharmaceuticals, Hanmi Pharmaceutical, Neutropenia, FDA, Pegfilgrastim, Hanmi, Spectrum, Medication, G-CSF, Partnership, CEO, SPPI, BLA, Patient, Nasdaq, DSN, Pharmaceutical industry, ROLONTIS® (eflapegrastim), ROLONTIS® (EFLAPEGRASTIM)

This investment represents a strengthening in the relationship that we have with Hanmi, said Tom Riga, President and CEO of Spectrum Pharmaceuticals.

Key Points: 
  • This investment represents a strengthening in the relationship that we have with Hanmi, said Tom Riga, President and CEO of Spectrum Pharmaceuticals.
  • Following a recent meeting in Korea with Spectrum management, we wanted to make this investment as a symbol of our confidence in their strategic direction moving forward, said Se-Chang Kwon, Ph.D., Chief Executive Officer at Hanmi Pharmaceutical.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Hanmi Announces Pricing of $110 Million Subordinated Debt Offering

Retrieved on: 
Wednesday, August 18, 2021
Federal Deposit Insurance Corporation, SEC, Small business, SBA, Federal Reserve, Small Business Administration, Securities Act of 1933, Risk, Keefe, Bruyette & Woods, Information technology, Hanmi, PPP, File, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Public sector banks in India, Community, Communication, HAFC, Time, Telephone, EDGAR, Prospectus, Sale, Hanmi Bank, Industry, SOFR, Legislation, Lists of disasters, Form, Community Reinvestment Act, Government, Paycheck Protection Program, S-3, NASDAQ, Failure, Income, Habit, Company, Terminology, GLOBE, Unemployment, Coronavirus, SEC filing, Annual report, COVID-19, Security (finance), Bank

LOS ANGELES, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (Hanmi), the holding company for Hanmi Bank (the Bank), today announced that it has priced an underwritten public offering of $110 million aggregate principal amount of its fixed-to-floating rate subordinated notes (the Notes) due 2031.

Key Points: 
  • LOS ANGELES, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (Hanmi), the holding company for Hanmi Bank (the Bank), today announced that it has priced an underwritten public offering of $110 million aggregate principal amount of its fixed-to-floating rate subordinated notes (the Notes) due 2031.
  • The offering is expected to close on August 20, 2021, subject to the satisfaction of customary closing conditions.
  • Each offering will be made only by means of a prospectus supplement and accompanying base prospectus.
  • Prospective investors should read the applicable prospectus supplement and base prospectus in the registration statement and other documents Hanmi has filed or will file with the SEC for more complete information about Hanmi and the relevant offering.

Hanmi Financial Declares Cash Dividend of $0.12 per Share

Retrieved on: 
Thursday, July 29, 2021
Hanmi, Dividend, Pacific City Bank

LOS ANGELES, July 29, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (Hanmi), the holding company for Hanmi Bank, today announced that its Board of Directors declared a cash dividend on its common stock for the 2021 third quarter of $0.12 per share.

Key Points: 
  • LOS ANGELES, July 29, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (Hanmi), the holding company for Hanmi Bank, today announced that its Board of Directors declared a cash dividend on its common stock for the 2021 third quarter of $0.12 per share.
  • The dividend will be paid on August 26, 2021 to stockholders of record as of the close of business on August 9, 2021.
  • Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 35 full-service branches and 9 loan production offices in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia.
  • Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses.

Hanmi Financial Corporation Announces Second Quarter 2021 Earnings and Conference Call Date

Retrieved on: 
Tuesday, July 13, 2021
Hanmi, NASDAQ, Companies, Service companies, Finance, Pacific City Bank

LOS ANGELES, July 13, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation(Nasdaq: HAFC) (Hanmi), the holding company for Hanmi Bank, today announced that it will report second quarter 2021 financial results at the market close on Tuesday, July 27, 2021.

Key Points: 
  • LOS ANGELES, July 13, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation(Nasdaq: HAFC) (Hanmi), the holding company for Hanmi Bank, today announced that it will report second quarter 2021 financial results at the market close on Tuesday, July 27, 2021.
  • Management will host a conference call that same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results.
  • Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 35 full-service branches and 9 loan production offices in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia.
  • Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses.

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 17, 2021
INDIANA, Economy of the United States, Life sciences, Communication, Forward-looking statement, Eli Lilly and Company, Hanmi, Incyte, Eli Lilly, Lilly

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases.
  • The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
  • For more information, please visit: www.innoventbio.com .\nThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties.
  • The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements.

Athenex Provides First Quarter 2021 Corporate and Financial Update

Retrieved on: 
Thursday, May 6, 2021
Food and Drug Administration, United States Public Health Service, Hanmi, Royalty payment

We expect to have a type A meeting with the FDA before end of the second quarter.\xe2\x80\x9d said Johnson Lau, CEO and Chairman of Athenex.

Key Points: 
  • We expect to have a type A meeting with the FDA before end of the second quarter.\xe2\x80\x9d said Johnson Lau, CEO and Chairman of Athenex.
  • We hope to align with the FDA, work to resolve its concerns and reach agreement on the path forward required to obtain approval.
  • The decrease was primarily due to the royalty payment to Hanmi incurred in 2020 on the license revenue from Xiangxue.
  • In 2020, the Company recorded a significant amount of revenues from international customers as a result of the global pandemic.

Hanmi Financial Increases Quarterly Cash Dividend By 20%

Retrieved on: 
Thursday, April 29, 2021
Hanmi, Dividend

b'LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (\xe2\x80\x9cHanmi\xe2\x80\x9d), the holding company for Hanmi Bank, today announced that its Board of Directors declared a cash dividend on its common stock for the 2021 second quarter of $0.12 per share, up 20% from $0.10 per share in the prior quarter.

Key Points: 
  • b'LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC) (\xe2\x80\x9cHanmi\xe2\x80\x9d), the holding company for Hanmi Bank, today announced that its Board of Directors declared a cash dividend on its common stock for the 2021 second quarter of $0.12 per share, up 20% from $0.10 per share in the prior quarter.
  • The dividend will be paid on May 27, 2021 to stockholders of record as of the close of business on May 10, 2021.\n\xe2\x80\x9cI am very pleased to announce the increase of our quarterly dividend for the second time this year,\xe2\x80\x9d said Bonnie Lee, President and Chief Executive Officer.
  • Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses.
  • We undertake no obligation to update such forward-looking statements except as required by law.\n'

Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Hanmi Pharmaceutical, Hanmi, Poziotinib, Trademark, Marketing, Poziotinib

The company holds an exclusive license from Hanmi Pharmaceuticals to develop, manufacture, and commercialize poziotinib worldwide, excluding Korea and China.

Key Points: 
  • The company holds an exclusive license from Hanmi Pharmaceuticals to develop, manufacture, and commercialize poziotinib worldwide, excluding Korea and China.
  • Poziotinib is currently being investigated by the company and Hanmi in several mid-stage trials in multiple solid tumor indications.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Hanmi Financial Corporation Resumes Stock Repurchase Plan

Retrieved on: 
Tuesday, February 16, 2021
Stock market, Corporate finance, Equity securities, Share repurchase, Hanmi, Stock, Targeted repurchase

LOS ANGELES, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation(Nasdaq: HAFC) (the Company), the holding company for Hanmi Bank, today announced that it will resume purchases of its common stock pursuant to its current Stock Repurchase Plan (the Plan).

Key Points: 
  • LOS ANGELES, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation(Nasdaq: HAFC) (the Company), the holding company for Hanmi Bank, today announced that it will resume purchases of its common stock pursuant to its current Stock Repurchase Plan (the Plan).
  • Under the Plan, originally announced on January 24, 2019, the Board of Directors authorized the Company to repurchase up to 5% of its outstanding shares or approximately 1.5 million shares of its common stock.
  • On April 30, 2020, the Company announced the suspension of the Plan due to the uncertainty arising from the COVID-19 pandemic.
  • As of February 12, 2021, approximately 989,600 shares of the Companys common stock remain available for repurchase under the current Plan.